HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

Abstract In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX ERBB2 mRNA score as a prognostic predictor, aiming to tailor treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, Elia Seguí, Esther Carcelero, Pablo Tolosa, Jesús Soberino, Manuel Alva, Tomás Pascual, Laura Lema, Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey, Luis Manso, Angela Aguirre, Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo, Patricia Galván, Esther Sanfeliu, Guillermo Villacampa, Wesley Buckingham, Mercedes Marín-Aguilera, Laia Paré, Patricia Villagrasa, Charles M. Perou, Julia Maues, Fara Brasó-Maristany, Eva Ciruelos, Aleix Prat
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00753-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00753-8

Similar Items